Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186].

doi:10.1016/j.lfs.2022.120430

科研成果详情

题名	Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186].
作者	Chen, Xingxing 1; Ge, Wenhua 2; Dong, Tiancheng 1; Hu, Jie 1; Chen, Lingzhi 3; Fan, Xiaofang4; Gong, Yongsheng5; Zhou, Hao6
发表日期	2022-04-02
发表期刊	Life sciences 影响因子和分区
语种	英语
原始文献类型	Published Erratum
ISSN	0024-3205
EISSN	1879-0631
卷号	298 页码:120430
DOI	10.1016/j.lfs.2022.120430
收录类别	PUBMED
URL	查看原文
PubMed ID	35379487
TOP期刊	TOP期刊
引用统计	被引频次[WOS]：0 [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/155168
专题	附属第一医院温州医科大学
作者单位	1.Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.; 2.Stomatological Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710004, China.; 3.Department of Clinical Laboratory, Wenzhou Central Hospital, Wenzhou 325000, China.; 4.Department of Hypoxia Medical Research Laboratory, Wenzhou Medical University, Wenzhou 325000, China.; 5.Department of Hypoxia Medical Research Laboratory, Wenzhou Medical University, Wenzhou 325000, China. Electronic address: fxbwzmc@126.com.; 6.Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Electronic address: wyzh66@126.com.
第一作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Chen, Xingxing,Ge, Wenhua,Dong, Tiancheng,et al. Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186].[J]. Life sciences,2022,298:120430.
APA	Chen, Xingxing., Ge, Wenhua., Dong, Tiancheng., Hu, Jie., Chen, Lingzhi., ... & Zhou, Hao. (2022). Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186].. Life sciences, 298, 120430.
MLA	Chen, Xingxing,et al."Corrigendum to "Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats" [Life Sci. 224 (2019) 177-186].".Life sciences 298(2022):120430.